294
Views
7
CrossRef citations to date
0
Altmetric
PRECOCIOUS PUBERTY

Inhibin B as a screening tool for early detection and treatment monitoring of central precocious puberty

, , , ORCID Icon, &
Pages 768-771 | Received 10 Oct 2019, Accepted 16 Jan 2020, Published online: 12 Mar 2020
 

Abstract

Anti-Müllerian hormone (AMH) and inhibin B are considered possible biomarkers of central precocious puberty (CPP). The aim of this study was to evaluate serum levels of AMH and inhibin B, to investigate their regulatory patterns, and to study their clinical significance in girls with CPP. In total, 48 girls with CPP and 35 age-matched prepubertal control girls were enrolled in the study. AMH and inhibin B levels were determined in the CPP and control groups. In the patient group, AMH and inhibin B levels were evaluated during 1 year of gonadotropin releasing hormone analog (GnRHa) treatment. The mean inhibin B level in the CPP group was significantly higher than that in the control. AMH levels were not different between the two groups. After GnRHa treatment. AMH and inhibin B levels decreased significantly. Based on the ROC analysis, the cutoff value for inhibin B to determine CPP was 19.59 pg/mL, with 83.3% sensitivity and 82.9% specificity, and the area under the curve was 0. 852. Inhibin B was useful for determining CPP and the therapeutic effects of GnRHa treatment in girls with CPP. AMH interacted, in part, with the hypothalamo-pituitary gonadal axis, but its clinical implications in CPP should be further investigated.

摘要

抗苗勒氏管激素(AMH)和抑制素B被认为是中枢性性早熟(CPP)可能的生物学标志物。本研究的目的是检测CPP女童血清AMH和抑制素B水平, 探讨其调节规律及其临床意义。总共有48名患有CPP的女孩和35名年龄相匹配的青春期前女孩作为对照参加了这项研究。测定CPP组和对照组的AMH和抑制素B水平。CPP组在促性腺激素释放激素类似物(GnRHa)治疗1年内检测AMH和抑制素B水平。CPP组的平均抑制素B水平明显高于对照组。两组间AMH水平无明显差异。经GnRHa治疗后, AMH和抑制素B水平明显降低。根据ROC分析, 抑制素B预测CPP的截断值为19.59pg/mL, 灵敏度为83.3%, 特异度为82.9%, 曲线下面积为0.852。抑制素B可用于CPP的预测以及GnRHa治疗CPP的疗效观察。AMH部分与下丘脑-垂体性腺轴相互作用, 但其在CPP中的临床意义有待进一步研究。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Disclosure statement

The authors have no conflicts of interest to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.